Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

被引：22

作者：

Qualls, David A.

Lambert, Nicholas ^{[1
,2
]}

Caimi, Paolo F. ^{[3
]}

Merrill, Mwanasha ^{[4
]}

Pullarkat, Priyanka ^{[5
]}

Godby, Richard C. ^{[6
]}

Bond, David A. ^{[6
]}

Wehmeyer, Graham T. ^{[9
,10
]}

Romancik, Jason ^{[11
]}

Amoozgar, Behzad ^{[12
]}

Leslie, Lori ^{[11
]}

Nastoupil, Loretta J. ^{[1
,13
,14
]}

Crombie, Jennifer L. ^{[4
]}

Abramson, Jeremy S. ^{[4
]}

Khurana, Arushi ^{[6
]}

Nowakowski, Grzegorz S. ^{[5
]}

Maddocks, Kami ^{[7
,8
]}

Rutherford, Sarah C. ^{[9
,10
]}

Kahl, Brad ^{[12
]}

Okwali, Michelle ^{[1
]}

Buege, Michael J. ^{[1
]}

Seshan, Venkatraman ^{[1
]}

Batlevi, Connie L. ^{[1
]}

Salles, Gilles ^{[1
,15
,16
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Div Hematol Malignancies, New York, NY 10065 USA

[2] Baylor Coll Med, Dept Med, Houston, TX USA

[3] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[5] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA USA

[6] Mayo Clin, Div Hematol & Oncol, Dept Internal Med, Rochester, MN USA

[7] Ohio State Univ, James Canc Hosp, Columbus, OH USA

[8] Ohio State Univ, Solove Res Inst, Columbus, OH USA

[9] Weill Cornell Med, Dept Med, Meyer Canc Ctr, New York, NY USA

[10] New York Presbyterian Hosp, New York, NY USA

[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[12] Washington Univ, Sch Med, Dept Med, St Louis, MO USA

[13] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[15] Weill Cornell Med Coll, New York, NY 10065 USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

BLOOD | 2023年 / 142卷 / 26期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1182/blood.2023021274

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL. © 2023 The American Society of Hematology

引用

页码：2327 / 2331

页数：5

共 50 条

[21] Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study
Wasterlid, Tove
Hasselblom, Sverker
Joelsson, Joel
Weibull, Caroline E.
Rassidakis, Georgios
Sander, Birgitta
Smedby, Karin E.
BLOOD CANCER JOURNAL, 2021, 11 (05)
[22] Clinical features, treatment options and outcomes in primary cutaneous B-cell lymphomas: a real-world, multicenter, retrospective study
Nikolaou, Vasiliki
Koumprentziotis, Ioannis-Alexios
Papadavid, Evangelia
Patsatsi, Aikaterini
Diavati, Stavrianna
Tsimpidakis, Antonios
Kruger-Krasagakis, Sabine
Doxastaki, Aikaterini
Marinos, Leonidas
Kaliampou, Stella
Gerochristou, Maria
Koumourtzis, Marios
Pappa, Vasiliki
Kypraiou, Efrosini
Kouloulias, Vassilis
Angelopoulos, Konstantinos
Machairas, Alexandros
Vassilakopoulos, Theodoros
Papadopoulou, Vasiliki
Tsamaldoupis, Athanasios
Georgiou, Elisavet
Koletsa, Triantafyllia
Stratigos, Alexander
Siakantaris, Marina
Angelopoulou, Maria
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024,
[23] The use of tafasitamab in diffuse large B-cell lymphoma
Duell, Johannes
Topp, Max
Salles, Gilles
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[24] A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Larsen, Thomas S.
Manzke, Oliver
Leibovitz, Daniel
Arbushites, Michael
BLOOD, 2022, 140 : 12077 - 12078
[25] Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma
Chien, Hsu-Chih
Morreall, Deborah
Patil, Vikas
Rasmussen, Kelli M.
Li, Chungyang
Yong, Christina M.
Burningham, Zachary
Masaquel, Anthony
Halloran, Mary
De Long-Sieg, Elisha
Schulz, Mathias
Sauer, Brian C.
Halwani, Ahmad S.
FUTURE ONCOLOGY, 2020, 17 (04) : 411 - 422
[26] Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis
Moore, Donald C.
Eagers, Keren A.
Janes, Amanda
Pineda-Roman, Mauricio
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 239 - 241
[27] Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States
Saverno, Kimberly
Nastoupil, Loretta
Feinberg, Bruce
Galvin, John
Pathak, Prathamesh
Amoloja, Theresa
Gentile, Danielle
Asgarisabet, Parisa
Epperla, Narendranath
BLOOD, 2024, 144 : 2375 - 2376
[28] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
Lu, Q.
Huang, H.
Tang, S.
Wang, Y.
Yang, D-H
DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
[29] Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis
Mendes, Joao Ricardo Belo Freitas
Couleur, Laurine
Manca, Chloe
Frossard, Valerie
Nabergoj, Mitja
ANNALS OF HEMATOLOGY, 2025, 104 (02) : 1291 - 1293
[30] RE-MIND: comparison of tafasitamab plus lenalidomide (L-MIND) vs lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
Zinzani, P. L.
Rodgers, T.
Marino, D.
Frezzato, M.
Barbui, A. M.
Castellino, C.
Meli, E.
Fowler, N. H.
Salles, G.
Feinberg, B.
Kurukulasuriya, N.
Tillmanns, S.
Parche, S.
Dey, D.
Fingerle-Rowson, G.
Ambarkhane, S.
Winderlich, M.
Nowakowski, G.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 59 - 59

← 1 2 3 4 5 →